Welte, TobiasDellinger, R. PhillipEbelt, HenningFerrer, Miguel DOpal, Steven MSinger, MervynVincent, Jean-LouisWerdan, KarlMartin-Loeches, IgnacioAlmirall, JordiArtigas, AntonioIgnacio Ayestaran, JoseNuding, SebastianFerrer, RicardSirgo Rodriguez, GonzaloShankar-Hari, ManuAlvarez-Lerma, FranciscoRiessen, ReimerSirvent, Josep-MariaKluge, StefanZacharowski, KaiBonastre Mora, JuanLapp, HaraldWoebker, GabrieleAchtzehn, UteBrealey, DavidKempa, AxelSanchez Garcia, MiguelBrederlau, JoergKochanek, MatthiasReschreiter, Henrik PeerWise, Matthew PBelohradsky, Bernd HBobenhausen, IrisDalken, BenjaminDubovy, PatrickLangohr, PatrickMayer, MonikaSchuettrumpf, JoergWartenberg-Demand, AndreaWippermann, UlrikeWolf, DanieleTorres, Antoni2024-09-062024-09-062018-04Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer M, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018 Apr;44(4):438-48. Epub 2018 Apr 9.0342-4642http://hdl.handle.net/20.500.13003/10607https://hdl.handle.net/20.500.12105/22531Purpose: The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing similar to 23% immunoglobulin (Ig) M, similar to 21% IgA, and similar to 56% IgG as add-on therapy for patients with severe community-acquired pneumonia (sCAP). Methods: In this double-blind, phase II study (NCT01420744), 160 patients with sCAP requiring invasive mechanical ventilation were randomized (1:1) to trimodulin (42 mg IgM/kg/day) or placebo for five consecutive days. Primary endpoint was ventilator-free days (VFDs). Secondary endpoints included 28-day all-cause and pneumonia-related mortality. Safety and tolerability were monitored. Exploratory post hoc analyses were performed in subsets stratified by baseline C-reactive protein (CRP; >= 70 mg/L) and/or IgM (<= 0.8 g/L). Results: Overall, there was no statistically significant difference in VFDs between trimodulin (mean 11.0, median 11 [n = 81]) and placebo (mean 9.6; median 8 [n = 79]; p = 0.173). Twenty-eight-day all-cause mortality was 22.2% vs. 27.8%, respectively (p = 0.465). Time to discharge from intensive care unit and mean duration of hospitalization were comparable between groups. Adverse-event incidences were comparable. Post hoc subset analyses, which included the majority of patients (58-78%), showed significant reductions in all-cause mortality (trimodulin vs. placebo) in patients with high CRP, low IgM, and high CRP/low IgM at baseline. Conclusions: No significant differences were found in VFDs and mortality between trimodulin and placebo groups. Post hoc analyses supported improved outcome regarding mortality with trimodulin in subsets of patients with elevated CRP, reduced IgM, or both. These findings warrant further investigation.enghttp://creativecommons.org/licenses/by-nc/4.0/TrimodulinPolyclonal antibodySevere community-acquired pneumoniaAdd-on therapyImmunoglobulin Mresearch articleAttribution-NonCommercial 4.0 International29632995444438-44810.1007/s00134-018-5143-71432-1238Intensive Care Medicineopen accessResultado del TratamientoInfecciones Comunitarias AdquiridasIsotipos de InmunoglobulinasRecién NacidoFemeninoFactores InmunológicosTerapia CombinadaMasculinoMétodo Doble CiegoHumanosPersona de Mediana EdadAncianoAnciano de 80 o más AñosNeumoníaAntibacterianosRespiración Artificial2-s2.0-85045110708431171300004L621611467